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Snakebite is predominantly an occupational disease affecting poor rural farmers in tropical regions and was
recently added to the World Health Organisation list of Neglected Tropical Diseases (NTD). We document an
overview of methodologies developed and deployed in the Myanmar Snakebite Project, a foreign aid project
largely funded by the Australian Government, with the core aim to “improve outcomes for snakebite patients”. A
multidisciplinary team of experts was assembled that worked in a collaborative manner with colleagues in
Myanmar, first to identify problems related to managing snakebite and then develop interventions aimed to
improve selected problem areas. A broad approach was adopted, covering antivenom production, antivenom
distribution and health system management of snakebite. Problems identified in antivenom production included
poor snake husbandry resulting in poor survival of captive specimens, lack of geographical diversity; poor horse
husbandry, resulting in high mortality, inadequate stock acquisition protocols and data collection, and inap-
propriate immunisation and bleeding techniques; and inadequate production capacity for freeze dried antivenoms
and quality control systems. These problems were addressed in various ways, resulting in some substantial im-
provements. Antivenom distribution is being reorganised to achieve better availability and utilisation of stock.
Health system management of snakebite was assessed across all levels within the area selected for the study, in
Mandalay region. A comprehensive community survey indicated that hospital statistics substantially under-
estimated the snakebite burden, and that access to care by local villagers was delayed by transport and cost issues
compounded by lack of antivenom at the most peripheral level of the health service. A health system survey
confirmed under-resourcing at the local village level. Prospective case data collection initiated at tertiary hospitals
indicated the extent of the snakebite burden on health resources. Interventions initiated or planned include
training of health staff, development of a core of senior trainers who can “train the trainers” nationwide in a
sustainable way, development and deployment of management guidelines and algorithms for snakebite and a
distribution of solar powered fridges to remote health facilities to allow storage of antivenom and prompt
treatment of snakebite cases before transfer to major hospitals, thereby reducing the “bite to needle” time.n's & Children's Hospital, North Adelaide, SA 5006, Australia.
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Snakebite is arguably the most important venom induced disease
(VID) (WHO, 2007) globally. Estimates of its annual incidence and
mortality, range up to >5 million cases and >100,000 deaths annually
(Chippaux, 1998; Kasturiaratne et al., 2008; Swaroop and Grab, 1954). A
detailed community study in India provided a strong data set indicating
at least 45,000 deaths annually due to snakebite, significantly in excess of
the “high” estimates in a global study estimating snakebite rates and
mortality, where “South Asia” (included India, Pakistan, Bangladesh) had
a stated mortality range of 14 k to 33 k deaths/year (Mohapatra et al.,
2011). The World Health Organisation (WHO) currently lists the annual
global mortality from snakebite as 81,000 to 138,000 (WHO, 2017).
Snakebite also extracts a financial burden, causing victims, their families
and health services significant economic loss (Habib et al., 2015; Kas-
turiaratne et al., 2017). The plight of snakebite patients in the developing
world, where this is predominantly an occupational disease of poor rural
farmers, has been highlighted by groups such as the Global Snakebite
Initiative (Gutierrez et al., 2010, 2013; Warrell, 2010), culminating in
listing of snakebite as a global health issue at the World Health Assembly
in Geneva in May 2016, followed by its inclusion in the WHO list of
Neglected Tropical Diseases (NTDs) in 2017. These efforts highlight the
urgent need to develop strategies to improve outcomes for snakebite
patients, especially in the rural tropics where incidence is highest.
Most published approaches to tackling the global snakebite problem
focus on restricted aspects, mainly the inadequate availability of safe,
effective and affordable antivenoms (Gutierrez et al., 2014; Warrell et al.,
2013; Williams et al., 2010, 2011). Ensuring availability of appropriate
antivenom (AV) is a priority, but availability of AV alone is not the
complete solution for improving patient outcomes in snakebite (Gutier-
rez, 2014; Harrison et al., 2011, Harrison and Gutierrez, 2016).
We herein report the development and deployment of a comprehen-
sive strategy to deliver a sustainable solution for snakebite in impov-
erished rural areas of a developing nation with a known high snakebite
burden.
2. Methods
The Myanmar Snakebite Project is a joint Australia-Myanmar project
funded through the Australian Government Department of Foreign Af-
fairs and Trade (DFAT), with support from the Government of Myanmar
(Ministry of Industry and Ministry of Health and Sports) and in-kind
support from the University of Adelaide, SA Health (Women's & Chil-
dren's Hospital, Royal Adelaide Hospital), Seqirus Ltd, Venom Supplies
Ltd., University of Sydney, CSIRO Australian Animal Health Laboratory
and a number of volunteer experts. Its stated aim is “to improve outcomes
for snakebite patients”.
The Project was established under the auspices of the University of
Adelaide, Faculty of Health Sciences, with executive control (Executive
Team; ET) by 3 university staff (full time or clinical associates) providing
skills and experience in clinical toxinology, renal medicine and public
health, all of whom had prior contact with the health sector in Myanmar.
Through this contact these individuals were approached in 2014 by
colleagues in Myanmar, requesting assistance with their snakebite
problem. The Project proposal was developed by the ET and colleagues in
the Myanmar Ministry of Health andMinistry of Industry, in consultation
with colleagues in Australia.
This process, through both discussions and visits to Myanmar to
identify issues, prior to funding being granted, ascertained that there
were 3 principal areas requiring intervention, in the interests of a broad
approach to the problem, rather than concentration on a single aspect
such as antivenom. The 3 principal areas were:
 Antivenom production
 Antivenom distribution2
 Health system strengthening for more effective management of
snakebite
The ET assembled a team encompassing a broad range of relevant
skills and experience (Fig. 1). Team members were drawn from those
with relevant expertise, both in Myanmar, and from elsewhere, most
notably Australia, as the nation funding the Project. In this paper, where
the “Project” undertakes an activity, this implies relevant members of the
Project team undertook the activity, including both non-Myanmar
members of the team and Myanmar members of the team and, where
appropriate, other Myanmar personnel, in a collaborative and coopera-
tive manner. A key Project requirement was that activities jointly
involved those from within and outside Myanmar, as equal partners.
Without that equal partnership involving many colleagues in Myanmar,
the Project could not have achieved the results it has and this is therefore
a core component of methodology (i.e. development and implementation
of interventions to address AV production, distribution and health system
strengthening).
2.1. Selection of project sites for activity and intervention
Myanmar is sufficiently large (676,578 km2) andwell populated (>52
million) to make it impossible to conduct activities across the entire
country with the resources available to the Project, therefore it was
necessary to select a suitable site and sub-sites as interventional foci. To
achieve this the Project team consulted senior Ministry of Health and
Sport officials, examined Ministry statistics on recorded rates of snake-
bites in each region and shortlisted several potential sites that met the
criteria of significant snakebite case load, accessibility, and local re-
sources and enthusiasm for the aims of the Project. Senior team members
then undertook visits to selected sites, and, using these criteria, selected a
major focus site and two sub-sites.
2.2. Antivenom production
The Project supported initial fact-finding visits to the Myanmar gov-
ernment antivenom production facility, with strong support from the
Government of Myanmar through the Minister/Deputy Minister of In-
dustry and key staff at the facility. This identified several problem areas:
2.2.1. Venom production
Globally accepted methodology for antivenom production involves
venom collection followed by inoculation into the production animals.
This requires collection, housing and regular venom extraction from
snakes. In Myanmar, at present, there are 2 monospecific antivenoms,
raised against Russell's viper (Daboia siamensis) and monocled cobra
(Naja kaouthia). Within a given species there may be considerable venom
variability across its geographic range, a problem well documented for
the Western Russell's viper Daboia russelii (Prasad et al., 1999).
Snakes must be healthy and preferably be long lived in captivity. The
Project therefore determined, through visits by experts in clinical tox-
inology and herpetology, the health of captive snakes used, their care in
captivity, seeking potential problems and possible solutions.
2.2.2. Antibody production
As is usually the case in antivenom production, horses are the prin-
cipal production animals in Myanmar. The WHO global standard for
antivenom production includes measures of horse health and longevity in
production, in addition to immunisation and plasma product processing
requirements. The Project determined, through its advisory visits by
experts in clinical toxinology, veterinary medicine, antivenom produc-
tion, the health of the horses and the facilities available for their care,
immunisation and plasma collection. During this process it became
apparent that documentation of the health of individual horses was
inadequate. A database was therefore developed and deployed to
improve data collection. Equipment was provided, with associated staff
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health (haematocrit (PCV) and Equine Infectious Anemia (EIA) exposure
status). In addition, staff were trained to conduct autopsies on horses
dying during production, to ascertain causes of death.
2.2.3. Antivenom processing and production
The Project assessed the existing antivenom production methodolo-
gies against WHO global standards, using advisory visits by experts in
clinical toxinology and antivenom production.
2.3. Antivenom distribution
The Project investigated problems relating to antivenom distribution
(quantity, availability to users in the health system, factors restricting
availability) through exploratory visits by experts in clinical toxinology,
public health, antivenom production and through subsequent meetings
and discussions with local stakeholders in the Ministry of Industry and
Ministry of Health and Sports. This approach was supplemented by data
collected through other Project activities, including community surveys,
health system analyses and prospective case data collection.
2.4. Health system management of snakebite
The Project identified some key questions that demanded answers,
through some initial visits before funding was secured, followed by
further enquiries:
What is the true extent of snakebite in the community?
The Project undertook a comprehensive, random sample community
survey designed to capture data on rates of snakebite, outcomes, first aid
knowledge and practices, care-seeking behaviour, sources of local care,
availability of health system resources, utilisation of those resources and
impediments to their implementation.
Within the chosen project areas 150 villages were randomly selected
with probability proportional to size. This resulted in a spread of villages
that optimized varying levels of health system access and in which access
to and use of various resources might be improved [Rural Health Centers
(RHCs), Station Hospitals (SHs), Township Hospitals (THs)]. Within
villages selection of study households was rigorously randomised. A team
of Myanmar enumerators was recruited through the Myanmar Ministry
of Health and Sport. They were trained to conduct the survey and were
deployed under the supervision of Project team leaders in public health
and epidemiology.
Which data about snakebite are currently available in the health system?
Initially, the Project team was given access to data on snakebite rates
and outcomes in the Myanmar government's health management infor-
mation system. However, these datasets lack data at population level,Fig. 1. Diagrammatic representation of Project staff sk
3
because patients may not seek help through the formal health system, or
may leave the system for social or economic reasons so that their data are
lost to the system.
Which data should be available to the health system to guide snakebite
management?
The Project team, using global standards, expert experience and dis-
cussions with Myanmar colleagues, developed a set of core pieces of
information that would assist decision making processes in snakebite
management within the health system.
What is the capacity of the health system to manage snakebite and what
skills are currently available among health system staff for snakebite
management?
The capacity of the health system to manage snakebite was assessed
through discussions with local experts and through a survey at each level
of the system within the Project study sites using a specifically developed
questionnaire.
What training is required for health system staff to improve snakebite
management?
The Project team, in collaboration with other Myanmar colleagues,
through a consultative process, guided by local conditions and knowl-
edge of clinical toxinology training developed by some team members
over a 20 year period, developed a curriculum for training that allowed
training of health staff to start in Project sites. Experiences and feedback
from this initial training allowed refinement of the in-service training
curriculum and training.
What resources are required by the health system to improve snakebite
management?
Through the processes outlined above, we initially determined which
resources were needed. Snakebite management algorithms and guide-
lines were then produced (Figs. 2–6), through a review process involving
local users, to ensure their practicability, applicability and, most
importantly, local acceptance.
3. Results
3.1. Selection of project sites for activity and intervention
Several key geographic sites were considered including in Yangon
and Magwe Divisions, but Mandalay Division proved to be the best,
centered on Mandalay General Hospital (MGH; a 2,500 bed teaching
hospital), which is a regional centre that admits at least 600 snakebite
patients annually, many with severe envenoming, including acute kidney
injury. Within the Mandalay health division, Madaya township (MTH)
and Kyaukse township (KTH) were chosen as sub-sites. In each, a central
township hospital serves a region with numerous smaller towns and
villages with Station Hospitals (SHs) or Rural Health Centers (RHCs).ill sets involved in each of the 3 project sections.
Fig. 2. Page 1 of snakebite management guide for Myanmar; overview of important assessment points. [Original graphic copyright © Julian White, used
with permission].
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Fig. 3. Page 2 of snakebite management guide for Myanmar; management algorithm. [Original graphic copyright © Julian White, used with permission].
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Fig. 4. Page 3 of snakebite management guide for Myanmar; algorithm guiding administration of antivenom. [Original graphic copyright © Julian White, used
with permission].
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Fig. 5. Page 4 of snakebite management guide for Myanmar; list of clinical issues to consider. [Original graphic copyright © Julian White, used with permission].
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Fig. 6. How to perform the 20 Minute Whole Blood Clotting Test (20WBCT) provided together with the management guide for Myanmar (Figs. 1–4). [Original graphic
copyright © Julian White, used with permission].
J. White et al. Toxicon X 1 (2019) 100001
8
Fig. 7. Monthly horse mortality over 3½ years showing dramatic decline as the
Project progressed and interventions were implemented. The Project work
commenced towards the end of 2014. Data provided up to February 2018.
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with key medical consultant staff who became actively involved in
developing both teaching and educational material and programs and
advising on development and deployment of case data collection. To
achieve this, the active support of the Ministry of Health and Sport and
direct involvement as a senior Project team member of the national Di-
rector of the Ministry Snakebite Program were vital, emphasising the
collaborative approach of this Project.
3.2. Antivenom production
Ministry of Industry; Burma Pharmaceutical Industries factory site
(BPI), Insein, Yangon and Hmawbe site, near Yangon.
3.2.1. Venom production
Early scoping visits identified major problems in snake husbandry,
specifically a poor snake house, multiple snakes per cage, poor snake
health and markedly reduced life span and poor geographic spread of
utilised snakes. The Project team, specifically experts in herpetology and
clinical toxinology, worked with the local Myanmar staff managing
snakes to advise on new methods of snake care, including providing on-
site training for key staff at a model snake venom extraction facility in
Australia. Snakes were moved to a new purpose-built facility, housed in
individual clear plastic containers and managed appropriately, resulting
in improvement in snake health. Longevity for Russell's viper remains a
problem because of difficulty persuading most snakes to feed appropri-
ately, and solutions to this problem continue to be explored. The issue of
geographic variability of snakes to ensure adequate venom variability
within pooled venom was identified, and a program to more widely
source snakes from within Myanmar has been proposed.
3.2.2. Antibody production
Horse husbandry and high horse mortality were identified as key
problems impeding antivenom production. The high horse mortality
resulted in an inability to supply local demand, thereby requiring
importation of foreign antivenoms that were less well targeted against
Myanmar snake venoms. The causes of poor horse health and high
mortality were not immediately apparent as horse health data was poorly
recorded and many variables were in operation. As this was a critical
problem the Project initiated multiple changes simultaneously to ensure
rapid improvement. For this part of the Project, team experts in veteri-
nary medicine and antivenom production were critical.
The Project sourced simple technology to allow routine PCV mea-
surement to assess horse health at all stages of the induction, immuni-
sation and bleeding process. This was combined with better assessment
of EIA status and vet-supervised visual assessment of horse health.
Moving horses to a healthier environment allowing free paddock use
rather than limitation to stalls, plus dietary improvements were also
initiated. Veterinary assessments revealed that poor horse paddock and
facility design were resulting in avoidable injuries to horses with health
and mortality consequences, therefore changes to facilities to mitigate
against such hazards were initiated. Horse facility staff were provided
training on clinical and post-mortem examination techniques, both in
Australia and on-site. Reuse of needles used in immunisation was noted
and introduction of single-use needles recommended. Replacement of
multiple-use bleeding systems with single use isolated systems to main-
tain sterility was recommended and suitable systems sourced and intro-
duced. Physical separation (quarantine) of incoming stock horses from
existing horses, prior to clearance for infectious disease was recom-
mended and initiated and similar separation of horses positive for EIA
from the rest of the herd was recommended and initiated.
The horse database was developed specifically for this facility and a
staff person employed to ensure accurate data entry, with a view to
implementing this database as an ongoing live management system to
replace the pre-existing and limited manual card system. The horse
database will be handed over to BPI as the Project winds down and BPI9
have indicated they intend using it as an ongoing management tool.
Another staff member was provided training in Australia to develop
ELISA-based detection systems to determine antibody response levels in
immunised horses, thereby reducing reliance on destructive small animal
(mouse) testing. This ELISA assay is now in routine use at BPI.
The combined effect of these multiple interventions was, over the first
3 years of the project, a dramatic fall in horse mortality (Fig. 7), with
improved horse health, longevity, a reduced requirement for annual
replacement of horses and a consequent significant rise in production
capacity and fall in cost per vial. At time of writing the facility is on track
to regain sustainable sufficient antivenom production to meet all
Myanmar needs.
3.2.3. Antivenom processing and production
In the first 2 years of the project the principal focus was increasing
antibody output. Subsequent efforts have targeted a move towards pro-
duction of a higher proportion of freeze dried antivenom, and improved
quality control of final product. The former is of importance because it
became apparent early in the Project that electricity supply throughout
Myanmar, especially in rural areas, is unreliable, thus causing cold chain
maintenance issues for liquid antivenoms. Freeze dried antivenoms do
not have such rigorous cold chain requirements and generally have a
longer shelf life which is advantageous if deployed to isolated rural en-
vironments where usage may be low, but availability should be main-
tained given the potentially long delays in seeking antivenom at a larger
(but distant) health facility.
The Myanmar producer already had identified this issue and sought
Project funding support to assist in the purchase of a suitable freeze drier.
The Project contributed a substantial sum to enable purchase of the
freeze drier which came online in 2017. As an interim measure the
Project funded purchase of a limited number of solar powered fridges for
deployment to selected isolated RHCs and SHs to allow storage of current
liquid antivenoms, thereby allowing reduced “bite to needle” time in
administering antivenom.
The issue of ongoing antivenom quality control will now be
addressed, involving input from Australian and other antivenom pro-
duction experts and training of Myanmar staff in required techniques.
The importance of good quality control of antivenom product cannot be
over-emphasised. An ongoing challenge is persuading local producers to
mount the required clinical trials for newly developed antivenom
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upgraded production facilities, utilizing new equipment and processes.
3.3. Antivenom distribution
The Project, having better established rates of bites and antivenom
requirements through activities in other parts of the Project, has now
established a coordinating committee, bringing together relevant senior
personnel from theMinistry of Industry andMinistry of Health and Sport,
to determine a policy on antivenom distribution nationally and develop
and deploy a process to achieve this.
3.4. Health system management of snakebite
3.4.1. Community survey
The community health survey involved 144 villages, 4276 house-
holds and 19,877 people. Detailed analysis of this data is ongoing, but
initial analysis indicates that snakebite is more common and deaths more
frequent than currently recorded through the health system. This will
have clear implications for health system resource allocation in future
and may provide key data to design strategies to improve patient and
system outcomes.
3.4.2. Community empowerment
Education and training directed towards disease prevention, first aid
skills and information promoting early transfer of patients to suitable
health care facilities where appropriate is amongst the most important
aspects of addressing public health problems. Therefore the Project
focused on community empowerment through education and skills
development. This was achieved through various interventions. As part
of the process of gathering data, the Project staff and all primary care
outreach workers in the government sector were trained to deliver public
education on prevention of snakebite. The data collecting staff provided
education to more than 4,000 respondents for the community survey.
The primary care outreach workers were also trained to conduct com-
munity meetings and provide health education and basic first aid skills.
These meetings were conducted in more than 200 villages in the Project
sites, providing education to another 6,000 people. Furthermore, the
project, in collaboration with government health care staff, identified
community health activists in 150 villages and working with the
Myanmar Red Cross Society, provided extensive training to these com-
munity ‘champions’ who will act as a community resource and can pass
on knowledge and skills to the rest of the local community.
3.4.3. Primary care staff training
Consultations with the healthcare staff across primary and secondary
care facilities indicates that if “bite to needle” time is to be reduced, staff
training in newly provided RHC resources (particularly antivenom use) is
essential. The Project has commenced training of RHC staff within the
study areas.
3.4.4. Case data collection
Through a collaborative process a case data collection system using a
tailor-designed and built database and derived data collection forms has
been developed and data collection commenced, first at MGH and now at
a number of other hospitals. Site specific data on snakebite incidence,
antivenom utilisation and clinical outcomes is now provided to Myanmar
based clinicians and health administrators via quarterly reports gener-
ated by the Project.
3.4.5. Provision of education to health workers
The Project has worked with Myanmar colleagues to develop health
worker training in snakebite management, based on pre-existing re-
sources developed in Myanmar and supplemented by skills and knowl-
edge provided through Project senior team members. Initial training has
been provided to health staff at multiple levels within the Project activity10zones. The long term requirement is to develop a core of senior trained
personnel (“master trainers”) within the Ministry of Health and Sport
who will “train the trainers”, allowing deployment of training in snake-
bite management to be deployed in a sustainable manner nationwide.
Project senior team members are working with senior Ministry staff to
develop a process to achieve this goal and once staff are identified and
appointed by the Ministry, high level training of these “trainers” will
commence using materials and information already developed
(Figs. 2–6). In coordination with this, new curricula for snakebite are
being developed at the undergraduate level (medicine, nursing, allied
health), for implementation country-wide.
Management plans and algorithms to guide treatment of snakebite
patients have been officially developed by the Project team and the
government regional health services in Mandalay (Figs. 2–6). These
clinical support documents have been provided directly to clinicians in
all Project sites. The acceptance and utilisation of these tools has been so
high amongst local Myanmar health workers that they are now being
adopted in other regions within the country independent of Project ac-
tivity. The Ministry of Health and Sports have indicated they will deploy
this written material countrywide.
4. Discussion
Snakebite is still an important disease in many parts of the rural
tropics and affects particularly the rural poor, hence it is a predominantly
occupational disease affecting farmers. The numbers of people affected
dwarfs those affected by many officially recognised Neglected Tropical
Diseases, yet snakebite does not yet enjoy the international resources
brought to bear on those NTDs. It is hoped that official WHO recognition
of snakebite as an NTD will now allow focus of international resources to
tackle this problem. This issue has been, in recent times, highlighted in
the literature, as earlier mentioned (Gutierrez, 2014; Gutierrez et al.,
2010, 2013, 2014, Habib et al., 2015; Harrison et al., 2011, Harrison and
Gutierrez, 2016; Kasturiaratne et al., 2017; Warrell, 2010; Warrell et al.,
2013; Williams, 2015; Williams et al., 2011). The Myanmar Snakebite
Project provides a practical model for addressing snakebite as a health
issue in these environments, with a holistic approach covering many
aspects.
Addressing public health problems requires a people-centered pri-
mary health care (PHC) approach, which incorporates comprehensive
and integrated health care with the community at the centre of devel-
opment (WHO, 2008). Integrated care is about making available to
people a continuum of health education, preventive actions, and effective
treatment and rehabilitation. The project adopted the PHC approach and
continuum of care through education, first aid training, training of pri-
mary care workers, training of hospital based staff and strengthening of
services and resources at all facilities from rural health centers to hos-
pitals. It has been noted that the key to successful international assis-
tance, in terms of strengthening health systems and effective
management of public health problems, by collaborative projects, is to
strengthen rather than undermine the local control, facilitate strength-
ening of governmental health service structures, and working through
sustained equitable professional relationships between locals and expa-
triates (Feiffer, 2003). With this in mind, the Project international experts
worked hand in hand with the local partners to facilitate development
within the government sector rather than opening up the Project's own
“shop-front”. The collaborative, cooperative nature of the intervention,
emphasised foreign experts working with and alongside Myanmar col-
leagues to consider and develop and deploy solutions. Technology and
skills transfer, with a focus on strengthening the existing resources, is a
key to achieve long term local sustainability rather than reliance on
outside support.
The community survey provided clear evidence that the actual com-
munity impact of snakebite was more substantial than official govern-
ment hospital-based data might indicate, in line with studies elsewhere
(Ediriweera et al., 2016; Iliyasu et al., 2015; Lam et al., 2016;
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epidemiologic study, managed by experts in public health, provides
essential information required for understanding the health impact of
snakebite and the development of appropriate system-level responses to
improve outcomes.
The case data collection, once fully analysed, will provide valuable
information that can be correlated with the community survey to indicate
specific problem areas requiring intervention. However, even crude data
from this process provides useful information for other areas of health
system planning. An example is antivenom use in total vials; the current
case data indicates that in the MGH it is BPI Viper Antivenom that is used
predominantly (8,848 vials), with only a small amount of BPI Cobra
Antivenom used (30 vials), information which can be used to ensure
appropriate antivenom stocking by the Ministry of Health and Sport and
efficient production targets for each antivenom, to meet actual need, by
the Ministry of Industry, potentially avoiding wasteful overproduction of
Cobra Antivenom. Similar data, once available for other parts of
Myanmar, can indicate whether this pattern is universal, or whether the
patterns of antivenom use are region-specific, again allowing better tar-
geting of antivenom production, inter-Ministry purchasing, and deploy-
ment to areas of need.
The dramatic improvements in horse health and longevity have
allowed rapid progress towards national antivenom self-sufficiency for
Myanmar, a result which arguably justifies the simultaneous deployment
of interventions in multiple areas, even though that compromised ability
to isolate specific factors contributing to poor horse outcomes. It is likely
that horse health is impacted in a complex multifactorial manner by
diverse variables including amultitude of potential infections, immediate
environment, nutrition, pre-existing health, genetics, levels of care pro-
vided, staff skills and training, production requirements, the latter
potentially conflicting with best practice horse health care. By continuing
to closely monitor aspects of horse health and husbandry, alongside an-
tivenom production parameters such as immunisation and bleeding
schedules, emerging issues can quickly be detected and remedial action
taken. Implementing a database driven field management system for this
aspect of antivenom production poses challenges, including resistance
amongst older or long-time staff used to old methodologies and un-
comfortable with newer technology and methods. Adequate education,
training and encouragement may be applied to overcome this unfamil-
iarity. Demonstrated success of interventions and new methodologies of
care may assist in enthusing existing staff about support for a process of
continuous improvement.
While it may be too soon to determine the effectiveness of Project
interventions in the area of pre-hospital and in-hospital care of snakebite
patients, studies elsewhere have indicated the importance of appropriate
training at all levels within the health system and, similarly, the value of a
coordinated national approach and use of guiding protocols (Monzavi
et al., 2015). The Ministry of Health and Sports, Myanmar, have indi-
cated a desire to fully implement Project recommendations, including a
nation-wide adoption of the snakebite diagnostic and treatment algo-
rithms and information developed by the Project and continuation of
snakebite case data collection across many hospitals, to monitor patient
outcomes and resource utilisation.
Limitations of this study include the necessity to limit epidemiologic
studies, community education and case data collection to circumscribed
areas because of the logistics involved. A wider community survey of
snakebite, across a diverse array of regions and habitats may have
delivered a more comprehensive view of the impact of snakebite. How-
ever, by selecting areas with known or expected significant snakebite
incidence, representative of the broad areas of risk involving much of the
Myanmar rural farming population, we consider our data is representa-
tive and scalable to estimate approximate national risk profiles. It will not
cover lesser populated regions with different habitat and snake fauna,
such as hilly forested areas and coastal areas where traditional fishing
may risk exposure to sea snake bites. Our success with establishing
collection, preservation and expert identification of snakes involved in11snakebite was less successful than we had hoped for, in part because it
proved more difficult than anticipated to gain permission for and suc-
cessfully establish systems to enable snake collection. We recommend
that establishing viable snake collection systems be prioritized early in
future projects similar to ours. Similarly, early prioritization of field
snake collection by herpetologists would have provided our project with
valuable data. Unfortunately, logistic issues prevented us from under-
taking such field work until late in the Project, limiting effectiveness.
Conversely, the delayed field collection allowed us to better prioritise
which snakes were of particular interest. Establishing effective working
relationships between locals and external project staff is critical, but can
take considerable time and effort, particularly in relation to senior bu-
reaucrats within key areas of government. We were fortunate to already
have some key contacts at the commencement of our project. In devel-
oping and undertaking foreign aid projects such as ours there is a risk that
scarce government resources may be stretched too thinly by trying to
meet project requests, with potentially adverse outcomes. We managed
this problem by ensuring we funded sufficient local resources as part of
the project, to avoid such negative impacts on existing resources, a
particular issue when interfacing with a very busy health system.
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